Savara, Inc. (SVRA): Price and Financial Metrics
SVRA Price/Volume Stats
| Current price | $2.86 | 52-week high | $3.01 |
| Prev. close | $2.90 | 52-week low | $1.08 |
| Day low | $2.81 | Volume | 329,000 |
| Day high | $2.97 | Avg. volume | 243,435 |
| 50-day MA | $2.08 | Dividend yield | N/A |
| 200-day MA | $1.82 | Market Cap | 326.23M |
SVRA Stock Price Chart Interactive Chart >
Savara, Inc. (SVRA) Company Bio
Savara Inc., a clinical-stage specialty pharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is based in Austin, Texas.
Latest SVRA News From Around the Web
Below are the latest news stories about SAVARA INC that investors may wish to consider to help them evaluate SVRA as an investment opportunity.
Savara to Present at the Jefferies Healthcare ConferenceAUSTIN, Texas, June 02, 2023--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Jefferies Healthcare Conference on June 9, 2023 at 10:30 am ET/7:30 am PT. A live webcast of the fireside chat will be available on Savara’s website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days. |
Independent Director of Savara David Ramsay Buys 4.8% More Shares \Potential Savara Inc. ( NASDAQ:SVRA ) shareholders may wish to note that the Independent Director, David Ramsay... |
Why Shares of Savara Jumped on TuesdayThe company released first-quarter earnings and said it had completed a phase 3 trial enrollment for its lead therapy. |
Savara Reports First Quarter Financial Results and Provides Business UpdateAUSTIN, Texas, May 15, 2023--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2023 and provided a business update. |
Savara Announces New Employment Inducement GrantAUSTIN, Texas, May 05, 2023--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees. |
SVRA Price Returns
| 1-mo | 40.89% |
| 3-mo | 13.49% |
| 6-mo | 77.64% |
| 1-year | 104.29% |
| 3-year | 17.70% |
| 5-year | -69.64% |
| YTD | 84.52% |
| 2022 | 25.00% |
| 2021 | 7.83% |
| 2020 | -74.33% |
| 2019 | -40.82% |
| 2018 | -48.99% |
Loading social stream, please wait...